In a prominent use case, AI-HOPE-PM analyzed data from the TCGA COAD dataset to investigate how financial strain affects outcomes among folinic acid, fluorouracil, and oxaliplatin (FOLFOX)–treated patients with CRC with TP53 mutations (Figure 2). Here, TP53 is linked to colorectal carcinoma.